About Dr Jesse Kumar

I am a Consultant Endocrinologist in the United Kingdom with dual accreditation for endocrinology, diabetes and general internal medicine (GMC Specialist Register 4681470). I am also accredited with ARSAC (Administration of Radioactive Medicinal Products) for radio-iodine therapy for benign thyroid conditions (hyperthyroidism and thyroid nodules/goiter).

I was appointed as a Consultant Endocrinologist in 2006 after finishing my higher specialist training in South Thames Deanery (Guy’s & St Thomas’ Hospital – London, Kent & Sussex) and held the following posts since my appointment: Clinical Director, Lead for Diabetes Commissioning and Lead Physician since my appointment at Maidstone and Tunbridge Wells NHS Trust.I am a specialist in the thyroid, adrenal, calcium disorders, hypogonadism, medical weight loss, and general endocrinology. I have an established interest in research and was the Principle Investigator (PI) and Sub-Investigator (SI) in several worldwide multi-center trials since 2006 both for phase 3 (pre-market) & 4 (post-release) trials. This has helped gather extensive insight for my clinical practice, provide numerous publications/presentations in international and national journals and conferences and the pleasure of supervising doctors for their higher medical education (MSc, etc).

My ethos is in providing easily accessible comprehensive care with evidence-based medicine at the core in addition to optimal nutrition, exercise and humanities of art as a comprehensive path to health. I am a firm believer in an interface of modern technology with humanities as an adjunct to delivering effective outcomes in clinical care.

I am registered with various professional institutions including MPS, BMA, ETA, etc. I am married with three children, I speak five languages and maintain a keen interest in fitness.

Combination Thyroxine + T3 treatment in hypothyroidism – ETA guidelines 2012 help prescribing in hypothyroidism

Combination treatment with thyroxine and T3 has always remained controversial and uncommon (particularly the armour treatment) and the reluctance of endocrinologists to prescribe (which is very understandable). The controversy i.e. the paucity of evidence in medical  literature to support T4+T3 treatment – Vs – persistence of symptoms on adequate treatment with thyroxine (despite normal TSH) and reported improvement […]

Another weight reducing diabetes treatment approved by European Authority – Dapagliflozin

FORXIGA™ (dapagliflozin) has recently (mid-Nov 2012) been approved in European Union for treatment of type 2 diabetes – A wonderful ‘concept to reality’ story which originates from the ‘cider’ qualities of increasing loss of glucose through the kidney by inhibition of SGLT-2 receptors. It may seem confusing as diabetes itself causes glycosuria (loss of glucose […]